Clinical trials
for patients
Learn about available clinical trials
-
April 10, 2024Pamplona/MadridIn recruitmentEarly phase
R2810-ONC-2045 Clinical trial of cemiplimab with BNT116 compared to cemiplimab as first-line treatment in patients with non-small cell lung cancer
The study is investigating an investigational drug called BNT116 that is initially given alone and then combined with cemiplimab (in this document, both BNT116 and cemiplimab will be referred to as a "study drug" and together as the "study drugs"). The study focuses on patients with advanced non-small cell lung cancer (NSCLC). The purpose of the study is to evaluate the safety and tolerability of TNB116 in monotherapy and in combination with cemiplimab, as well as the efficac... -
April 10, 2024MadridIn recruitment
MK-2870-005 Phase 3 clinical trial to compare the efficacy and safety of MK-2870 in monotherapy versus physician-choice treatment in participants with endometrial cancer who have received prior chemotherapy.
The primary objective is to compare MK-2870 with physician's choice treatment (TEM) in terms of progression-free survival (PFS) according to RECIST 1.1 criteria, based on an independent blinded central review (ICER). -
April 8, 2024PamplonaIn recruitment
PF305 Trial to evaluate user experience with FARAVIEWTM technology for treating atrial fibrillation.
The purpose of this study is to collect data on atrial fibrillation and on the intervention performed. -
March 6, 2024Pamplona/MadridIn recruitmentEarly phase
CO43476 Clinical trial to evaluate the efficacy and safety of cevostamab in patients with relapsed or refractory multiple myeloma previously exposed to B-lymphocyte maturation antigen-targeted therapy.
The aim of this study is to determine the effects, good or bad, of cevostamab in participants with multiple myeloma that has worsened or not responded to treatment. -
February 15, 2024Pamplona/MadridIn recruitmentEarly phase
ASND0038 Randomized open-label phase II clinical trial of the TLR7/8 agonist TransCon in combination with pembrolizumab or pembrolizumab alone as neoadjuvant treatment in participants with head and neck squamous cell carcinoma.
The aim of this study is to learn what effects, good and bad, the study drugs have and to see if they work safely to shrink locally advanced resectable head and neck cancers, as well as to improve survival. -
February 12, 2024Pamplona/MadridIn recruitmentEarly phase
R5458-ONC-2256 Clinical trial of linvoseltamab in asymptomatic multiple myeloma patients at high risk of progression to multiple myeloma.
The objective of the study is to understand the safety and tolerability (how your body reacts to linvoseltamab) as well as the efficacy (to what extent linvoseltamab eliminates plasma cells and prevents the development of MM) of the study drug. -
February 8, 2024PamplonaIn recruitment
R5458-ONC-1826 Phase I/II FIH trial of REGN5458 in patients with relapsed or refractory multiple myeloma.
The main purpose of this study is to obtain more information on the safety of REGN5458 and to find the most appropriate dose of REGN5458 for the treatment of patients with multiple myeloma. -
January 29, 2024Pamplona/MadridIn recruitmentEarly phase
MK-2140-006 Clinical trial to evaluate the safety and efficacy of MK-2140 in patients with aggressive and indolent B-lymphoid neoplasms (waveLINE-006)
This trial is being conducted to: ¿ Evaluate the safety of zilovertamab vedotin when given as monotherapy or with nemtabrutinib. ¿ Test the efficacy of zilovertamab vedotin when given as monotherapy or with nemtabrutinib to treat B-lymphocyte cancers. -
January 25, 2024MadridIn recruitmentEarly phase
MK-6194-007 Clinical trial to evaluate MK-6194 in adult participants with non-segmental vitiligo.
The primary objective of the trial is to evaluate the efficacy of MK-6194 in terms of percentage change in F-VASI (Facial Vitiligo Area Score Index) score between baseline and week 24. -
January 24, 2024Pamplona/MadridIn recruitment
R1979-ONC-2075 Phase III, open-label, randomized clinical trial to compare the efficacy and safety of Odronextamab (REGN1979) combined with chemotherapy vs. Rituximab combined with chemotherapy in participants c
The primary objective of this study is to evaluate the safety, tolerability and dose-limiting toxicities (DLTs) of Odronextamab in combination with chemotherapy in participants with previously untreated FL.